partners

Rigel has signed partnerships with numerous leading pharmaceutical companies including, AstraZeneca, Daiichi Sankyo, Pfizer, Merck, Johnson & Johnson, and Novartis. During our collaborations with many of these organizations, they added new programs or extended their relationship with Rigel beyond the scope of the initial agreements. To date Rigel has received over $260 million from collaborations. These partnership programs are in addition to Rigel's own proprietary research and product development programs.

Rigel and AstraZeneca Awarded 'Licensing Deal of the Year' by Scrip for Fostamatinib Collaboration

Current partnership summary:

DEVELOPMENT   PARTNER   MECHANISM   INDICATION   YEAR

AstraZenenca  IL13/IL4 inhibition  Chronic Asthma  2012

BerGenBio  Axl kinase inhibition  Oncology  2011

AstraZeneca  Syk inhibition - oral  Rheumatoid arthritis  2010

Daiichi Sankyo  Ubiquitin ligase target  Oncology  2002